What is it about?
Thein vitrometabolic stability and transport mechanism of TM-25659, a novel TAZmodulator, was investigated in human hepatocytes and human liver microsomes (HLMs) based onthe preferred hepatobiliary elimination in rats. In addition, thein vitrotransport mechanism andtransporter-mediated drug–drug interactions were evaluated using oocytes and MDCKII cellsoverexpressing clinically important drug transporters.
Featured Image
Why is it important?
OATP1B1, OATP1B3, P-gp and MRP2 might be major transporters responsible for the pharmacokineticsand drug–drug interaction of TM-25659, although their contribution toin vivopharmacokinetics needsto be further investigated
Perspectives
understandingthe drug uptake and efflux transporters as well asdrug metabolizing enzymes that are responsiblefor the pharmacokinetics and drug response arecritical for new drug development.
Professor Im-Sook Song
Kyungpook National University
Read the Original
This page is a summary of: Transport characteristics and transporter-based drug-drug interactions of TM-25659, a novel TAZ modulator, Biopharmaceutics & Drug Disposition, December 2013, Wiley,
DOI: 10.1002/bdd.1883.
You can read the full text:
Contributors
The following have contributed to this page
